Novartis

E141505

Novartis is a global Swiss-based pharmaceutical company known for developing innovative medicines across a wide range of therapeutic areas.

All labels observed (11)

How this entity was disambiguated

Statements (53)

Predicate Object
instanceOf multinational corporation ⓘ
pharmaceutical company ⓘ
public company ⓘ
areaServed worldwide ⓘ
businessModel research-based pharmaceutical company ⓘ
CEO Vas Narasimhan ⓘ
country Switzerland ⓘ
foundedAsMergerOf Ciba-Geigy ⓘ
Sandoz ⓘ
foundedBy Ciba-Geigy ⓘ
Sandoz ⓘ
hasResearchCenter Basel ⓘ
linked to: Basel-Stadt

Cambridge, Massachusetts ⓘ
Shanghai ⓘ
headquartersLocation Basel ⓘ
linked to: Basel-Stadt

Switzerland ⓘ
inception 1996 ⓘ
industry biotechnology ⓘ
healthcare ⓘ
pharmaceuticals ⓘ
ISIN CH0012005267 ⓘ
languageOfWorkOrName English ⓘ
French ⓘ
German ⓘ
legalForm Aktiengesellschaft ⓘ
location Basel ⓘ
linked to: Basel-Stadt

Switzerland ⓘ
notableDrug Cosentyx ⓘ
Entresto ⓘ
Gleevec ⓘ
Kymriah ⓘ
Lucentis ⓘ
Tasigna ⓘ
productOrService biosimilars ⓘ
cardiovascular drugs ⓘ
cell and gene therapies ⓘ
generic medicines ⓘ
immunology drugs ⓘ
oncology drugs ⓘ
ophthalmology drugs ⓘ
prescription medicines ⓘ
stockExchange New York Stock Exchange ⓘ
SIX Swiss Exchange ⓘ
subsidiary Alcon ⓘ
Sandoz ⓘ
therapeuticArea cardiovascular diseases ⓘ
immunology ⓘ
neuroscience ⓘ
oncology ⓘ
ophthalmology ⓘ
tickerSymbol NOVN ⓘ
NVS ⓘ
website https://www.novartis.com ⓘ

How these facts were elicited

Referenced by (54)

Full triples — surface form annotated when it differs from this entity's canonical label.

Lucentis → marketedBy → Novartis ⓘ
Xolair → developedBy → Novartis ⓘ
Xolair → marketedBy → Novartis ⓘ
Pfizer → competitor → Novartis ⓘ
rivastigmine → wasDevelopedBy → Novartis ⓘ
Genmab → collaboratesWith → Novartis ⓘ
Alnylam Pharmaceuticals, Inc. → collaboratesWith → Novartis ⓘ
subject linked to: ALNY
Exelon Patch → marketedBy → Novartis ⓘ
fingolimod → developedBy → Novartis ⓘ
SPI → hasConstituent → Novartis AG ⓘ
linked to: Novartis
AveXis → parentOrganization → Novartis ⓘ
AveXis → acquiredBy → Novartis ⓘ
Novartis Gene Therapies → parentOrganization → Novartis ⓘ
subject linked to: AveXis
branaplam → developedBy → Novartis ⓘ
Ciba-Geigy → successor → Novartis ⓘ
Ciba-Geigy → mergerFormed → Novartis ⓘ
Ciba-Geigy → fate → merged to form Novartis ⓘ
linked to: Novartis
Sandoz → predecessorOf → Novartis ⓘ
Sandoz → partOf → Novartis ⓘ
Sandoz → parentOrganization → Novartis ⓘ
Sandoz → subsidiaryOf → Novartis International AG ⓘ
linked to: Novartis
Sandoz → successor → Novartis (as holding company for original Sandoz AG) ⓘ
linked to: Novartis
Novartis → hasSubsidiary → Novartis Oncology ⓘ
subject linked to: NOVN
linked to: Novartis
Novartis → hasBrand → Novartis Pharmaceuticals ⓘ
subject linked to: NOVN
linked to: Novartis
NVS → represents → Novartis AG ⓘ
linked to: Novartis
NVS → hasUnderlyingCompanyLegalName → Novartis AG ⓘ
linked to: Novartis
Vas Narasimhan → employer → Novartis ⓘ
Vas Narasimhan → boardMemberOf → Novartis Board of Directors ⓘ
linked to: Novartis
Alcon → formerOwner → Novartis ⓘ
Alcon → spinOffFrom → Novartis ⓘ
Gleevec → developedBy → Novartis ⓘ
Cosentyx → isManufacturedBy → Novartis ⓘ
Cosentyx → hasBrandOwner → Novartis Pharmaceuticals Corporation ⓘ
linked to: Novartis
Entresto → developer → Novartis ⓘ
Kymriah → developer → Novartis ⓘ
Kymriah → marketingAuthorizationHolder → Novartis Pharma AG ⓘ
linked to: Novartis
Tasigna → developedBy → Novartis ⓘ
SMI → includes → Novartis ⓘ